TITLE

Untitled

PUB. DATE
August 2011
SOURCE
Pharmaceutical Representative;Aug2011, Vol. 41 Issue 8, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. including the approval of the Food and Drug Administration (FDA) on the production and distribution of influenza vaccines in the country, the approval to use Boostrix vaccine from GlaxoSmithKline in tetanus prevention and the approval of Novartis AG's Arcapta Neohaler powder in the treatment of chronic obstructive pulmonary disease (COPD).
ACCESSION #
63988784

 

Related Articles

  • Fluarix for children.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA34 

    The article reports on the approval of Fluarix, a trivalent inactivated split virus influenza vaccine, for use in children 3-17 years of age.

  • FDA approves 2010-2011 influenza vaccines; offers updates on Afluria.  // Infectious Diseases in Children;Sep2010, Vol. 23 Issue 9, p24 

    The article focuses on the approval of seasonal influenza vaccines for 2010-2011 in the U.S. announced by the Food and Drug Administration (FDA) and the labeling changes done for Afluria to inform health care providers regarding increased rates of fever and febrile seizure in young children.

  • NICE to look again at basis for approving oseltamivir. Kmietowicz, Zosia // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p2 

    The article reports that Michael Rawlins, chairman of the National Institute for Health and Clinical Excellence (NICE) and Fiona Godlee, editor in chief of the British Medical Journal (BMJ) exchanged letters on approval of drug oseltamivir (Tamiflu), antiviral drug.

  • Withdraw approval for Tamiflu until NICE has full data. Godlee, Fiona // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p27 

    The article discusses National Institute for Health and Clinical Excellence (NICE) and author also asks various questions that confused her. It also discussed data given by NICE regarding Tamiflu and complains that apart from Roche no one was shown the data and that Roche claimed in Europe that...

  • We will look again at NICE appraisal of Tamiflu. Rawlins, Michael // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p28 

    The author discusses that as being with NICE, they will again look upon an appraisal of Tamiflu. He also discusses that any success is a result of the commitment and expertise of the staff and the support from the BMJ. The author states that he is not sure what additional measures the company...

  • Pharmacy operators emphasize importance of flu shots.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p37 

    The article reports on the importance of flu shots which has been stressed by pharmacy operators in the U.S.

  • Innovation Rebound.  // Pharmaceutical Representative;Sep2011, Vol. 41 Issue 9, p9 

    The article reports on the decline of new product approvals in the pharmaceutical industry of the U.S.

  • Severe flu season tests retail Rx.  // Chain Drug Review;2/4/2013, Vol. 35 Issue 3, p1 

    The article offers information on several drug chains across the U.S. including Walgreen Co., CVS/pharmacy Inc. and Rite Aid Corp. which are equipping them with flu vaccine to prevent the increasing number of influenza cases.

  • Pharma: Other News To Note.  // BioWorld Today;7/16/2012, Vol. 23 Issue 136, p3 

    This section offers news briefs on the U.S. pharmaceutical industry including the first Food and Drug Administration (FDA) approval received by Par Pharmaceutical Cos. Inc. for Labetalol HCI tablets and the FDA approval given to the abbreviated new drug application of Watson Pharmaceuticals Inc....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics